Glioblastoma: EU-funded "Actively personalized vaccination trial" success

The vision of therapeutic cancer vaccines is to effectively target and destroy all tumor cells while leaving healthy cells unharmed. The GAPVAC project was funded by the European Commission. Glioblastoma is the most aggressive form of brain cancer, unfortunately with only limited therapeutic options and only very poor prognosis. Thus, there is an urgent medical need for new therapeutic approaches. Previous experience in first vaccination trials has indicated encouraging immune responses to vaccinations in these patients.